CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)

Anti-CTLA-4-antibodies can induce long-lasting tumor remissions. However, only a few patients respond, necessitating the development of predictive companion biomarkers. Increasing evidence suggests a major role of epigenetics, including DNA methylation, in immunology and resistance to immune checkpo...

Descripción completa

Detalles Bibliográficos
Autores principales: Fietz, Simon, Zarbl, Romina, Niebel, Dennis, Posch, Christian, Brossart, Peter, Gielen, Gerrit H., Strieth, Sebastian, Pietsch, Torsten, Kristiansen, Glen, Bootz, Friedrich, Landsberg, Jennifer, Dietrich, Dimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139923/
https://www.ncbi.nlm.nih.gov/pubmed/33196890
http://dx.doi.org/10.1007/s00262-020-02777-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8139923/
https://www.ncbi.nlm.nih.gov/pubmed/33196890
http://dx.doi.org/10.1007/s00262-020-02777-4

Ejemplares similares